Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.
When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their largest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Is Apellis Pharmaceuticals Stock A Buy?
Apellis Pharmaceuticals stock has risen more than 5% past a 50.12 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech firm reported negative growth for both the top and bottom lines last quarter. ApellisPharmaceuticals is expected to release its next quarterly numbers on or around Apr. 28.
Apellis Pharmaceuticals stock holds the No. 94 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals, Vertex Pharmaceuticals and Amphastar Pharmaceutcls are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
